Seqster pursues mission to bring patients to center of healthcare

By Samantha Black, PhD, ScienceBoard editor in chief

December 21, 2021 -- Patient access to data is a critical mission for the healthcare industry, according to Ardy Arianpour, CEO and co-founder of Seqster, who recently spoke with ScienceBoard Editor in Chief, Samantha Black, PhD. The company is focused on developing much-needed data interoperability tools for the healthcare sector.

Arianpour co-founded Seqster in 2016 after working in the genomics space for 16 years. He noted that he was inspired to form the company by his mother who suffered from breast cancer and the work going on at the time around the BRCAI/II biomarkers. At this crossroads moment in his life when he was considering pursuing a PhD or MD degree, Arianpour decided to take a different path to pursue, mixing business and science.

Video loading ...

Seqster was founded to put the patient at the center of healthcare, according to Arianpour. The idea was to collect all electronic medical and health records, baseline genetic DNA data, continuous wearable monitoring data, etc., to generate a longitudinal health record in real time. Ultimately, the company's mission is to crack data interoperability.

What is data interoperability?

"I did not know that when I started Seqster that interoperability was going to be the No. 1 healthcare pain point problem," Arianpour said.

At its core, interoperability is the ability for different systems to communicate with each other. Arianpour explained that interoperability goes beyond clinical trial data and pharmaceutical companies -- it also encompasses information that physicians need to make informed treatment recommendations.

The pandemic shed light on how needed data interoperability tools are for the digital healthcare industry. Seqster's software as a service (SaaS) platforms and patient engagement solutions aggregate genomic data with all other medical data to provide accessible patient data.


Prior to co-founding Seqster, Arianpour was part of a successful business exit, which put him in a financial position where he could take risks. In 2016, he took the risk and invested $1 million in Seqster.

"My whole life's journey has been based on risk," he said. "I don't know how to do anything else."

Seqster was a "big gamble," Arianpour explained, but there was an X-factor at play. He knew that as long as he is behind it, he would be relentless in his mission and never deter from his efforts to place the patient at the center of healthcare.

Furthermore, he remains vigilantly focused on the journey and not the destination. Arianpour believes that dedication to building amazing products for patients by patients will ultimately result in business success. This is his plan A. Arianpour's No. 1 piece of advice for entrepreneurs is to always stick with plan A. "Plan A is execution, and failure has never been an option," he emphasized.

Seqster recently released its three major solutions: life sciences, real-world data, and patient engagement platforms. The company also announced a partnership with Olive to be listed in Olive's new universal marketplace, offering a solution that will automate health data integrations for Olive's enterprise payer and provider customers.

Arianpour concluded that Seqster is at an inflection point and will continue to form new partnerships. He hopes to bring interoperability to hyperspeed with exciting deals in the near future.

Do you have a unique perspective on your research related to genomics and data interoperability? Contact the editor today to learn more.


Elemental Machines acquires Tetra Lab Monitoring
Elemental Machines has acquired the Tetra Lab Monitoring business, including key hardware, talent, and novel asset integrations from TetraScience. The...
EY white paper details how the CGT industry can collaborate to advance the field
A transition from corporate individualism to teamwork and collaboration is necessary to meet the challenges that exist for companies in the cell and gene...
AI drug development market projected to reach $5.1B by 2025
The world market for AI applications in drug development is projected to reach $5.1 billion by 2025, an increase of more than $3.6 billion from the market...

Copyright © 2021

International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter